Terms: = Breast cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Prognosis
1293 results:
1. PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the egfr pathway.
Ma Y; Fang Z; Zhang H; Qi Y; Mao Y; Zheng J
Cell Death Dis; 2024 Apr; 15(3):199. PubMed ID: 38604999
[TBL] [Abstract] [Full Text] [Related]
2. A phenotypic screening approach to target p60AmotL2-expressing invasive cancer cells.
Fonseca P; Cui W; Struyf N; Tong L; Chaurasiya A; Casagrande F; Zhao H; Fernando D; Chen X; Tobin NP; Seashore-Ludlow B; Lundqvist A; Hartman J; Göndör A; Östling P; Holmgren L
J Exp Clin Cancer Res; 2024 Apr; 43(1):107. PubMed ID: 38594748
[TBL] [Abstract] [Full Text] [Related]
3. Epidermal growth factor receptor inhibition potentiates chemotherapeutics-mediated sensitization of metastatic breast cancer stem cells.
Kar T; Dugam P; Shivhare S; Shetty SR; Choudhury S; Sen D; Deb B; Majumdar S; Debnath S; Das A
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2049. PubMed ID: 38522013
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients.
Wang M; Wei Z; Kong J; Zhao H
Diagn Pathol; 2024 Mar; 19(1):53. PubMed ID: 38509525
[TBL] [Abstract] [Full Text] [Related]
5. Mammalian enabled protein enhances tamoxifen sensitivity of the hormone receptor-positive breast cancer patients by suppressing the AKT signaling pathway.
He L; She C; Jiang S; Qi Z; Deng Z; Ji L; Cui Y; Wu J
Biol Direct; 2024 Mar; 19(1):21. PubMed ID: 38459605
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic Markers in Tyrosine Kinases Specific to Basal-like 2 Subtype of Triple-Negative breast cancer.
Limsakul P; Choochuen P; Jungrungrueang T; Charupanit K
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338684
[TBL] [Abstract] [Full Text] [Related]
7. Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various cancers.
Rubin E; Shan KS; Dalal S; Vu DUD; Milillo-Naraine AM; Guaqueta D; Ergle A
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256137
[TBL] [Abstract] [Full Text] [Related]
8. The emerging roles of CEACAM6 in human cancer (Review).
Wu G; Wang D; Xiong F; Wang Q; Liu W; Chen J; Chen Y
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38240103
[TBL] [Abstract] [Full Text] [Related]
9. Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer.
Zou H; Luo J; Guo Y; Deng L; Zeng L; Pan Y; Li P
Drug Resist Updat; 2024 Mar; 73():101051. PubMed ID: 38219531
[TBL] [Abstract] [Full Text] [Related]
10. Clinical significance and immune characteristics analysis of miR-221-3p and its key target genes related to epithelial-mesenchymal transition in breast cancer.
Fang Y; Zhang Q; Chen Z; Guo C; Wu J
Aging (Albany NY); 2024 Jan; 16(1):322-347. PubMed ID: 38189813
[TBL] [Abstract] [Full Text] [Related]
11. Deep Learning Prediction Boosts Phosphoproteomics-Based Discoveries Through Improved Phosphopeptide Identification.
Yi X; Wen B; Ji S; Saltzman AB; Jaehnig EJ; Lei JT; Gao Q; Zhang B
Mol Cell Proteomics; 2024 Feb; 23(2):100707. PubMed ID: 38154692
[TBL] [Abstract] [Full Text] [Related]
12. Metastatic Lymph Node 64 (MLN64) Expression in Gastric cancer: The Clinical and Molecular Implications in Drug Resistance.
Li AX; Zeng JJ; Khan E; Dou QP; Zhuang X; Ji EK; Ruge F; Martin TA; Jia S; Jiang WG
Cancer Genomics Proteomics; 2024; 21(1):30-40. PubMed ID: 38151289
[TBL] [Abstract] [Full Text] [Related]
13. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer.
Liu Z; Yu B; Su M; Yuan C; Liu C; Wang X; Song X; Li C; Wang F; Ma J; Wu M; Chen D; Yu J; Yu Z
BMC Med; 2023 Dec; 21(1):493. PubMed ID: 38087296
[TBL] [Abstract] [Full Text] [Related]
14. HER2-positive advanced biliary tract cancer responds to second-line pyrotinib therapy: a case report.
Liu L; Chen Y; Zhu X; Zhao L; Chen B
Anticancer Drugs; 2024 Mar; 35(3):298-301. PubMed ID: 38037743
[TBL] [Abstract] [Full Text] [Related]
15. Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab.
Franco AFDV; Malinverni ACM; Waitzberg AFL
Pathol Res Pract; 2023 Dec; 252():154917. PubMed ID: 37977031
[TBL] [Abstract] [Full Text] [Related]
16. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham MP; Lucas P; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857525
[TBL] [Abstract] [Full Text] [Related]
17. SGCE promotes breast cancer stemness by promoting the transcription of FGF-BP1 by Sp1.
Qiu T; Hou L; Zhao L; Wang X; Zhou Z; Yang C; Zhang H; Jiang D; Jiao B; Chen C
J Biol Chem; 2023 Nov; 299(11):105351. PubMed ID: 37838174
[TBL] [Abstract] [Full Text] [Related]
18. NAA20 recruits Rin2 and promotes triple-negative breast cancer progression by regulating Rab5A-mediated activation of egfr signaling.
Qiao L; Dong C; Jia W; Ma B
Cell Signal; 2023 Dec; 112():110922. PubMed ID: 37827343
[TBL] [Abstract] [Full Text] [Related]
19. [Mechanism of Astragali Radix-Curcumae Rhizoma in treating gastric cancer based on network pharmacology and experimental verification].
Tan XY; Tao J; Zhang Y; Gu RX
Zhongguo Zhong Yao Za Zhi; 2023 Sep; 48(18):5056-5067. PubMed ID: 37802848
[TBL] [Abstract] [Full Text] [Related]
20. Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now.
Qi X; Shi Q; Xuhong J; Zhang Y; Jiang J
Breast Cancer Res; 2023 Oct; 25(1):113. PubMed ID: 37789330
[TBL] [Abstract] [Full Text] [Related]
[Next]
